Arabic Arabic English English French French German German
dark

Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19

BetterLife Pharma Inc. is pleased to announce early positive in vitro results of its SARS-CoV-2 (“COVID-19”) anti-viral, recombinant human interferon alpha-2b (“rhIFN⍺2b” or “AP-003”), from the Dr. Stephen Barr Laboratory and state-of-the-art ImPaKT Facility at Western University (“UWO”). AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

White House Enlists Social Media Giants to Suppress Vaccine ‘Misinformation’

Next Post

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada’s National Research Council

Related Posts
Total
0
Share